Indication: Hematological Malignancies
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Acerta Pharma BV
